Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

MediLink Signs $1 Billion ADC Out-Licensing Rights Agreement with Roche

publication date: Jan 2, 2024

Suzhou MediLink Therapeutics out-licensed global rights for its pre-clinical c-Mesenchymal epithelial transition factor (c-Met) ADC to Roche in a $1 billion agreement. MediLink will work with Roche's R&D unit, China Innovation Center of Roche, to start a Phase I clinical trial of YL211. After the trial, Roche will responsible for all further development and commercialization globally. MediLink will receive $50 million in upfront and near-term milestone payments and $1 billion of later milestones, plus tiered royalties. Three months ago, MediLink out-licensed global rights for an HER ADC to BioNTech in a $1.1 billion agreement. More details....

Stock Symbols: (SIX: RO, ROG) (NSDQ: BNTX)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital